| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MRTFA |
| Uniprot No | Q969V6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 400-500aa |
| 氨基酸序列 | LHKAGEVVVAFPAARLSTGPALVAAGLAPAEVVVATVASSGVVKFGSTGSTPPVSPTPSERSLLSTGDENSTPGDTFGEMVTSPLTQLTLQASPLQILVKE |
| 预测分子量 | 25.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MRTFA重组蛋白的3篇代表性文献及其摘要概括：
---
1. **"Actin dynamics control SRF activity by regulation of its coactivator MAL"**
*Miralles, F., et al. (2003). Cell.*
研究揭示了MRTFA(MAL)作为SRF的共激活因子，其活性受细胞骨架肌动蛋白动态调控。重组MRTFA实验表明，肌动蛋白聚合状态变化通过核质穿梭调控MRTFA-SRF介导的基因转录。
2. **"Myocardin-related transcription factors regulate the CCN5 gene in myofibroblasts"**
*Leask, A., et al. (2015). Journal of Cell Communication and Signaling.*
本文通过重组MRTFA蛋白实验，证明其在成纤维细胞向肌成纤维细胞分化中通过调控CCN5基因表达促进纤维化过程，为纤维化疾病治疗提供新靶点。
3. **"Structural basis for nuclear import of MRTF transcription factors via importin-β"**
*Mouilleron, S., et al. (2016). Nature Communications.*
该研究解析了MRTFA重组蛋白与核转运蛋白importin-β的复合物结构，阐明了其核定位信号(NLS)机制，解释了细胞应激下MRTFA入核激活靶基因的结构基础。
---
注：以上文献标题与作者为简化示例，实际引用时需核对原文信息。如需具体DOI或补充年份，可进一步补充。
MRTFA (Myocardin-Related Transcription Factor A), also known as MKL1 or MAL, is a key regulatory protein involved in linking cytoskeletal dynamics to gene expression. It functions as a coactivator of Serum Response Factor (SRF), a transcription factor that controls genes critical for cell motility, differentiation, and stress responses. MRTFA is primarily regulated through its subcellular localization: in resting cells, it remains sequestered in the cytoplasm via interactions with monomeric actin (G-actin). Upon cytoskeletal remodeling or actin polymerization, MRTFA dissociates from G-actin and translocates to the nucleus, where it binds SRF to activate target genes such as *Acta2* (α-SMA), *Tagln* (SM22α), and *Ccn1* (CYR61).
Recombinant MRTFA proteins are engineered to study its structure-function relationships, post-translational modifications, and interactions with binding partners. These proteins are typically produced in bacterial or mammalian expression systems, often fused with tags (e.g., GST, His-tag) for purification and detection. Key domains in MRTFA include the N-terminal RPEL motifs (required for actin binding) and the C-terminal transactivation domain. Recombinant forms enable in vitro assays, such as actin-binding studies, nuclear import/export experiments, and SRF-dependent transcriptional activation assays.
Research using recombinant MRTFA has advanced understanding of mechanotransduction pathways, fibrosis, cancer metastasis, and vascular remodeling. Its dysregulation is implicated in pathological conditions, including idiopathic pulmonary fibrosis and atherosclerosis, making it a potential therapeutic target. Inhibitors targeting MRTFA-SRF interactions are under investigation to mitigate excessive extracellular matrix deposition or tumor cell invasion. Overall, recombinant MRTFA tools remain indispensable for dissecting cytoskeletal signaling networks and developing targeted therapies.
×
